Dr. Maurizio Zangari's Publications

The following list represents only a fraction of articles published by Dr. Maurizio Zangari and highlights only those published in 2005 or later. If you would like to see a complete list of Dr. Zangari's publications, please contact us.

Zangari M, Barlogie B, Cavallo F, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients . Blood Coagulation and Fibrinolysis. 2007 Oct; 18(7):595-8.

Zangari M, Esseltine DL, cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, and Tricot G. Predictive value of Alkaline Phosphatase for Response and Time to Progression in Bortezomib treated Multiple Myeloma Patients. American Journal of Hematology. 2007 Sep; 82(9):831-3.

Zangari M, Elice F, Fink L, and Tricot G. Hemostatic Dysfunction in Paraproteinemias and in Amyloidosis. Seminars in Thrombosis and Hemostasis. 2007 June;33(4):339-49.

Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy. 2007 Mar;7(3):307-15.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy Jr JD. The molecular classification of multiple myeloma. Blood 2006; 108(6): 2020-2028.

Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica 2006; 91(7): 964-967.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Barlogie B, Tricot G. Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma. Clinical Lymphoma and Myeloma 2006; 7(2): 109-114.

Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006; 134(4): 399-405.

Barlogie B., Zangari M., Bolejack V., Hollmig K., Hollmig K., Anaissie E., van Rhee F., Pineda-Roman M., Mohiuddin A., Crowley J. and Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6(6): 469-474.

Zangari M., Cavallo F., and Trico G. Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. Curr Pharm Biotechnol. 2006; 7(6):449-453.

Zangari M. Anticoagulation Regimens for Thalidomide and Lenalidomide. Clin Adv Hematol Oncol. 2006; 4(9): 658-659.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee CK, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 2006; 354: 1021-1030.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burn MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to Bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct;131(1):71-3.